| Identification | Back Directory | [Name]
PIRIBEDIL HYDROCHLORIDE | [CAS]
78213-63-5 | [Synonyms]
PiribedilHCl
PIRIBEDIL HYDROCHLORIDE
Piribedil dihydrochloride
2-(4-piperonyl-1-piperazinyl)pyrimidinehydrochloride
2-(4-piperonyl-1-piperazinyl)-pyrimidinhydrochloride
2-(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)-pyrimidinmonohydrochlor
2-[4-(1,3-BENZODIOXOL-5-YLMETHYL)-1-PIPERAZINYL]PYRIMIDINE HYDROCHLORIDE
2-[4-(1,3-BENZODIOXOL-5-YLMETHYL)-1-PIPERAZINYL]PYRIMIDINIE HYDROCHLORIDE
2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidinedihydrochloride | [Molecular Formula]
C16H19ClN4O2 | [MDL Number]
MFCD01689349 | [MOL File]
78213-63-5.mol | [Molecular Weight]
334.8 |
| Hazard Information | Back Directory | [Uses]
Piribedil dihydrochloride is a useful dopaminergic for biological research purposes. | [Biological Activity]
A direct dopamine agonist, in clinical use for treatment of dopaminergic system dysfunction. Recent work suggests that it is selective for the D 3 subtype, for which it has 20 times higher affinity than for D 2 , and possesses no significant affinity for D 1 ? receptors. | [in vivo]
Piribedil hydrochloride (intraperitoneal injection, 5, 15, 40 mg/kg ) alleviates the L-DOPA-induced dyskinesias in rats model of Parkinson’s disease[2].
Piribedil hydrochloride (oral gavage, 4-5 mg/kg, daily for 2 weeks) increases locomotor activity and reversal of motor deficits in adult common marmosets[3].
Piribedil hydrochloride (oral gavage, 150 mg/kg, daily for 21 days) inhibits MLL-r tumor growth and decreases the expression of MLL1 target genes in MV4;11 tumor xenografts[4]. | Animal Model: | Rat model of Parkinson’s disease[2] | | Dosage: | 5, 15, 40 mg/kg | | Administration: | Intraperitoneal injection, administered 5 min before administration of L-DOPA. | | Result: | Reduced turning behaviour and AD (axial dystonia), OD (orolingual dyskinesia) and FD (forelimb dyskinesia) at 5 and 40 mg/kg.
Increased LD (locomotive dyskinesias) at the 40 mg/kg.
|
| Animal Model: | Adult common marmosets[3] | | Dosage: | 4-5 mg/kg | | Administration: | Oral gavage, daily for 2 weeks | | Result: | Increased vigilance and alertness and reversed the downregulation of preprotachykinin mRNA induced by MPTP in rostral and caudal striatum. |
| [IC 50]
D2 Receptor; D3 Receptor |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|